user

Modulation of anthracycline resistance in poor-risk acute myeloid leukemia (AML) with SDZ PSC-833: Results of a phase I/II multicenter study.

被引：0
|
作者：
List, AF
Karanes, C
Dorr, R
Spier, C
Grogan, T
Greer, J
Moore, J
Weinberger, J
Schiller, G
Dalton, W
Pearce, T
Litchman, M
机构：
[1] UNIV ARIZONA, TUCSON, AZ 85721 USA
[2] WAYNE STATE UNIV, DETROIT, MI 48202 USA
[3] VANDERBILT UNIV, NASHVILLE, TN 37240 USA
[4] DUKE UNIV, DURHAM, NC 27706 USA
[5] LOUISIANA STATE UNIV HLTH SCI CTR, SHREVEPORT, LA 71105 USA
[6] UNIV CALIF LOS ANGELES, LOS ANGELES, CA 90024 USA
[7] SANDOZ, E HANOVER, NJ USA
来源：
BLOOD | 1996年 / 88卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1156 / 1156
页数：1
相关论文
共 50 条
  • [31] INTERIM ANALYSIS OF A PHASE I/II STUDY OF TIPIFARNIB AND BORTEZOMIB IN THE TREATMENT OF POOR RISK ADULT ACUTE MYELOID LEUKEMIA
    Paolini, S.
    Ottaviani, E.
    Lama, B.
    Salmi, F.
    Clissa, C.
    Curti, A.
    Finelli, C.
    Giannoulia, P.
    Iacobucci, I.
    Laterza, C.
    Papayannidis, C.
    Parisi, S.
    Piccaluga, P. P.
    Saglio, G.
    Fanin, R.
    Morabito, A.
    Vianelli, N.
    Baccarani, M.
    Martinelli, G.
    [J]. HAEMATOLOGICA, 2008, 93 : S89 - S89
  • [32] A PHASE I STUDY OF TIPIFARNIB AND BORTEZOMIB IN THE TREATMENT OF POOR RISK ADULT ACUTE MYELOID LEUKEMIA
    Paolini, S.
    Ottaviani, E.
    Larna, B.
    De Rosa, E.
    Laterza, C.
    Giannoulia, P.
    Iacobucci, I.
    Papayannidis, C.
    Parisi, S.
    Piccaluga, P. P.
    Salmi, E.
    Baccarani, M.
    Martinelli, G.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 211 - 211
  • [33] A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a Southwest Oncology Group study 9617
    Chauncey, TR
    Rankin, C
    Anderson, JE
    Chen, IM
    Kopecky, KJ
    Godwin, JE
    Kalaycio, ME
    Moore, DF
    Shurafa, MS
    Petersdorf, SH
    Kraut, EH
    Leith, CP
    Head, DR
    Luthardt, FW
    Willman, CL
    Appelbaum, FR
    [J]. LEUKEMIA RESEARCH, 2000, 24 (07) : 567 - 574
  • [34] Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study.
    Vey, N
    Kantarjian, H
    Beran, M
    O'Brien, S
    Cortes, J
    Giles, FJ
    Koller, C
    Estey, E
    [J]. BLOOD, 1998, 92 (10) : 235A - 235A
  • [35] A phase II study of temozolomide therapy for poor-risk patients aged ⩾60 years with acute myeloid leukemia: low levels of MGMT predict for response
    J M Brandwein
    L Yang
    A D Schimmer
    A C Schuh
    V Gupta
    R A Wells
    S M H Alibhai
    W Xu
    M D Minden
    [J]. Leukemia, 2007, 21 : 821 - 824
  • [36] A phase I study of busulfan consolidation/intensification therapy for patients with high risk acute myeloid leukemia (AML).
    Gharibo, M. M.
    Schaar, D.
    Rubin, A.
    Grospe, S.
    Dudek, L.
    Strair, R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 356S - 356S
  • [37] Gentuzumab-ozogamicin (GO) plus idarubicin (I) and cytarabine (C) as induction treatment for elderly patients with poor-risk cytogenetics acute myeloid leukemia (AML)
    Harousseau, Jean-Luc
    Recher, Christian F. R.
    Vey, Norbert
    Witz, Francis
    Lioure, Bruno B. L.
    Toumilhac, Olivier
    Himberlin, Chantal
    Bouscary, Didier
    Ifrah, Norbert N. I.
    [J]. BLOOD, 2007, 110 (11) : 544A - 545A
  • [38] GENTUZUMAB-OZOGAMICIN (GO) PLUS IDARLIBICIN (I) AND CYTARABINE (C) AS INDUCTION TREATMENT FOR ELDERLY PATIENTS WITH POOR-RISK CYTOGENETICS ACUTE MYELOID LEUKEMIA (AML), RESULTS OF GOELAMS LAMR04 STUDY
    Delaunay, J.
    Recher, C.
    Vey, N.
    Witz, E.
    Lioure, B.
    Tournilhac, O.
    Himberlin, C.
    Bouscary, D.
    Ifrah, N.
    Harousseau, J. L.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 17 - 17
  • [39] Autologous and allogeneic transplantation in cytogenetically defined high risk acute myeloid leukemia:: Results of the AML HD93 study.
    Schlenk, RF
    Döhner, K
    Fröhling, S
    del Valle, F
    Hartmann, F
    Pralle, H
    Fischer, JT
    Gunzer, U
    Pezzutto, A
    Weber, W
    Grimminger, W
    Preiss, J
    Haas, R
    Ho, AD
    Döhner, H
    [J]. BLOOD, 1998, 92 (10) : 294A - 295A
  • [40] Zarnestra™ (R115777) in patients with relapsed and refractory acute myelogenous leukemia (AML):: Results of a multicenter phase 2 study.
    Harousseau, JL
    Reiffers, J
    Lowenberg, B
    Thomas, X
    Huguet, F
    Fenaux, P
    Stone, RM
    Lancet, J
    Arani, R
    Rackoff, W
    Thibault, A
    [J]. BLOOD, 2003, 102 (11) : 176A - 176A
12345